Study Findings - A low-frequency missense variant in the SYCE2 gene increases the risk of pregnancy loss by 22% [1] - The variant affects the stability of a protein complex essential for homologous chromosome alignment during recombination [2] - The variant's effect on recombination is proportional to chromosome length, with longer chromosomes experiencing a larger effect [3] - The association with pregnancy loss may underestimate the variant's impact, as it does not account for embryos lost before pregnancy detection [3] Research Methodology - Over 114,000 women from Iceland, Denmark, the UK, USA, and Finland who experienced pregnancy loss participated in a genome-wide association study [1] - The study tested 50 million sequence variants to identify genetic factors associated with pregnancy loss [1] Company Background - deCODE genetics, a subsidiary of Amgen, is a global leader in analyzing and understanding the human genome [4] - The company has discovered genetic risk factors for dozens of common diseases using its unique expertise and population resources [4]

Amgen (AMGN) closed the latest trading day at $310.26, indicating a +1.56% change from the previous session's end. The stock exceeded the S&P 500, which registered a gain of 0.53% for the day. Meanwhile, the Dow gained 0.64%, and the Nasdaq, a tech-heavy index, added 0.19%.The the stock of world's largest biotech drugmaker has risen by 6.62% in the past month, leading the Medical sector's gain of 1.36% and the S&P 500's gain of 2.48%.The upcoming earnings release of Amgen will be of great interest to invest ...

Key PointsAnalysts forecast healthcare stocks to lead S&P this year in earnings increases.Humana, Elevance, Incyte, Insulet and Cigna are expected to be the biggest earnings gainers.Wall Street says many factors that had been pressuring the industry are largely gone, or already baked into forecasts.5 stocks we like better than AmgenWhile the healthcare sector delivered lackluster profit growth in 2023, it should change this year. Sector components forecast to show the biggest earnings year-over-year earning ...

malerapaso Introduction Last year, I started covering drug manufacturing giant Amgen Inc. (NASDAQ:AMGN). On June 30, I wrote an article titled "Amgen: A Healthcare Bargain With A 4% Yield." Since then, shares are up 41%, beating the 9.5% performance of the S&P 500 (SP500) by a wide margin. This rally restored the company's longer-term performance, as it is now up 240% over the past ten years (including dividends). This beats the strong performances of the S&P 500 and the Health Care Select Sector SPDR Fund ...

The latest trading session saw Amgen (AMGN) ending at $307.81, denoting a +1.09% adjustment from its last day's close. The stock fell short of the S&P 500, which registered a gain of 1.23% for the day. Elsewhere, the Dow gained 1.06%, while the tech-heavy Nasdaq added 1.7%.Shares of the world's largest biotech drugmaker have appreciated by 9.01% over the course of the past month, outperforming the Medical sector's gain of 3.16% and the S&P 500's gain of 0.94%.The investment community will be closely monitor ...

Amgen (AMGN) ended the recent trading session at $304.08, demonstrating a +0.2% swing from the preceding day's closing price. The stock outpaced the S&P 500's daily loss of 0.56%. Elsewhere, the Dow lost 0.25%, while the tech-heavy Nasdaq lost 0.59%.Heading into today, shares of the world's largest biotech drugmaker had gained 8.99% over the past month, outpacing the Medical sector's gain of 3.8% and the S&P 500's gain of 1.2% in that time.The investment community will be paying close attention to the earni ...

Amgen (AMGN) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.Over the past month, shares of this world's largest biotech drugmaker have returned +11.3%, compared to the Zacks S&P 500 composite's +3.1% change. During this period, the Zacks Medical - Biomedical and Genetics industry, which Amgen falls in, has gained 8.4%. The key question now is: What could be the stock's future directio ...

The FDA, on Thursday, announced there is no evidence that diabetes and obesity drugs belonging to the popular glucagon-like peptide-1 receptor agonists (GLP-1 RAs) class of medicines cause suicidal thoughts or actions.The GLP-1 segment is an important class of drugs for multiple cardiometabolic diseases and is gaining significant popularity. GLP-1 drugs work by mimicking the hormone GLP-1, resulting in weight loss, lowering hemoglobin A1c (HbA1c) and reducing cardiovascular risks. GLP-1 drugs are approved f ...

In the latest trading session, Amgen (AMGN) closed at $303.10, marking a -0.48% move from the previous day. The stock trailed the S&P 500, which registered a daily loss of 0.07%.Shares of the world's largest biotech drugmaker have appreciated by 8.15% over the course of the past month, outperforming the Medical sector's gain of 7.37% and the S&P 500's gain of 3.98%.The upcoming earnings release of Amgen will be of great interest to investors. In that report, analysts expect Amgen to post earnings of $4.70 p ...

I am a big fan of routines, as I've found that many poor investment decisions come from an undisciplined use of our time as investors. For me, a weekly scan for stocks making new three-month highs and lows has become a vital part of my own toolkit, as it helps me identify new leadership themes a little earlier on in the trend. I was surprised this week to note the large number of health care names represented on the new highs list. And it wasn't just one group or theme within the sector, but rather a broade ...